Rallybio Corporation

Healthcare · Biotechnology · United States

Last price 15.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 81.83M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to ...